Haibu Pharmaceutical | The pharm'≠aceutical innovation sharing and exch≈$®€ange conference was successfully≠αΩ held.

　　On January 10, 2023,↑₹ε the "Pharmaceutical Innovation Forγγ£γum, 2023 New Year Sharing and Exchange™§✔₩ Meeting" co-hosted by Haibu Pharmace♦£utical, Kelin Likang, and Tongchuang We™©iye was successfully₩™♦≈ held in Beijing Yizhγ±uang.

　　This forum invited Mr. Chα™<εen Feng, Vice President of Keli∏↓φ£n Likang, as the host of the ev☆∑σ♦ent, along with Mr. Qi Yanbin, Pa÷≈rtner of Tongchuang Weiyeσ∞→γ; Professor Lu Laichun from Tongren HΩ>↕&ospital; Dr. Wang Haisheng, F §♣∏ounder of Sihai Gene; and D≥×r. Di Wei, Deputy GenerΩ§"al Manager of Haibu Pharmaceutical as ®>keynote speakers to shar✘₩♠‌e their insights. Experts andφ✔ scholars from fields such as new drugπ↔∞≠ development, clinical r↔<®esearch, pharmaceutical production, ♣φand investment in the pharmaceuα÷tical health sector were also inv₽γ♦×ited to share and exchange$ Ω ideas.

　　After years of rapid devel₩→↑opment, China has become th‌↓φ∑e second-largest pharmaceutical♠₽ market in the world. In the ∞¥>λprocess of transitioning from a m♠≈ajor pharmaceutical c  ✘★ountry to a strong pha∞↕‍λrmaceutical country, the p €harmaceutical industry faceφ£φ↔s multiple challengeφ↔s in structural adjustment and tranπαβ₹sformation upgrades. Seeking∑≥ technological innovation is the cε♠ornerstone of sustainable de≤​™αvelopment.

　　Thematic Report

　　Welcome Speech: Liu ₹✘$∏Changru (Chairman and General Manε•₹ager of Haibu Pharmaceut <ical)

　　Host: Chen Feng (Vice President of Ke¥ ↑αlin Likang)

　　Speaker: Qi Yanbin (Part★☆ner of Tongchuang Weiε★ye)

　　Report Topic: "2022λ'$ Annual Review Analysis of Primary M✔×arket Financing in the ≥α∞εMedical Industry"

　　In reviewing 2022, there were a $ ¥£total of 996 financing events in C®'φhina's primary medical marke∑ ♦t (as of December 20), wh§δich is lower than in 2021. T≥®σ≠he amount raised decreased signific☆'←antly to CNY 126 billion, comβ¥parable to that in 2019. Excl↔λαuding IPO fundraising and strateg♥ ♦ic investments, there were 921 fi✔♠nancing events in the medical prima÷₩ry market in 2022. Tπ§ ₽he investment rounds mainly concentra​≠<ted on angel rounds and Serie‌♠ s A funding. Financing events acros←×±s various fields have♣‌ shown a significant d‍★ecline. The overall market finπ™ancing amount has dec♣∞reased much more than the  ★number of events. The ✘♣δmarket has shifted from being ho​↑¶t in 2021 to being calm <♣♥↕and rational. Due to valuation discr' ←↔epancies between primary and secon ¥dary markets, policy imp♥↕acts, and considerations for ¥≥returns on investment, fin &≥ancing across all fields is t&‍¥★rending towards early §™stages with increased ris÷ &‌ks; future investment institu∞γ₽₩tions will be more caut♣αious and professional.

　　Speaker: Professor Lu La↓¥≈ichun (Deputy Director of Institutio←±nal Affairs at Tongren Hospital₩±')

　　Report Topic: "Cliniα♥cal Research on Gene€  Therapy for Ophthalmology"

　　Gene therapy aims to modify or contr‍™'ol gene expression or alter biolo$↓☆λgical characteristics of living ελ✘cells for treatment; i∏α't is a technology that mo↓•difies an individual's ge∏♦nes to treat or cure diseases. In & σ±recent years, related research has pr•≥εoliferated globally like mushrooms afδ≈ter rain. China is no exc→‌☆eption; gene therapy ≈γ≥δresearch has seen explosive grow→♣λth with IND applications increa$♠sing from single dig₩↔¥☆its to triple digits betwe"σφ♦en 2017 and 2022 over five yea£∏↔rs. The unique structure and physio☆φ₩logical characteristics o"λ¥☆f the eye make ophthalmi βεπc diseases ideal candidates f ♣♣or gene therapy. The number of companie★×☆αs globally focusing on ophthalmic g✔ ene therapy continues to riε≈se; ophthalmology has become→≤ one of the most richly researche∞∏±d therapeutic areas currently unde→®r investigation. However¶✔₩α, many projects are still at early d ♠♣evelopment stages compared‍α to foreign counterparts wher✔←₽ e most projects started latφ♦≈€er than those abroad. Curren‌•™tly entering clinical rese≥£αarch are mainly gene augmen₽♠φ tation therapies for op•↕€hthalmology; several companies also hδΩave gene editing pipelines at prec✘Ωlinical stages but d✘✘o not yet master new techno​✘δlogical therapies domestically. Gene₽γ therapy brings new hope f‌★ ≠or patients but requires na≥•tional support; scientists, entrepr&∞‍∞eneurs, and regulatory bod®α↕ies must cooperate to achi≈">eve breakthroughs in scientifi€₽σc research while master∏≤ing core technologies and i♣≤βmproving policies and regulat≈§''ions to guide healthy indus♥€±±try development better serve patients "&£λand benefit society.

　　Speaker: Dr. Wang Haiσσ™£sheng (Founder & CEO of Siha₽>★i Gene)

　　Report Topic: "The Role of ₩ ♥φAntisense Oligonucleotid♦↔→es on RNA and New Drug Developm♥₩​∞ent"

　　(ASO) Antisense oligonucleot↔®ide drugs are a class that ↔✘£λspecifically binds target ge♣Ω'ne DNA or mRNA through s≥≤equence specificity to inhibit¶™ gene expression at the gen≠£ σetic level as molecular₹&★≤ drugs regulated at this level. These​≥↓ drugs have unique therapeutic≠× effects on certain genetic defect diseαδ≈ases with over thirty years' historΩγ>₽y related research availab‌​✔₹le now in China following Sp σinraza's approval int"€ o national health insurance director&✔♣<y ASO gradually enters public vie₩₹ε←w since then In year twenty twenty ® co-founder CSO Lai Fan publishe≠•&™d his new findings regarding ASO mechan​©&isms as corresponding aut★♠↓hor Molecular Cell linking n♠®uclear single-stranded nucleic acid '₩↔ ASO splicing transcription terminatio®εβ♦n proposing its molecular action mechan±∞∏¶ism This discovery alloπ£←✔ws better design dev>≈×elop RNA drugs based o₩§n single-stranded antiδ✘sense nucleic acid ASπ ™O laying down molecular biolog£<‌y foundation for ASO's action within c₩'​ell nucleus Thus R&‌≠;D surrounding ASO drugs ₩ enters new stage.

　　Speaker: Dr. Di Wei (Deput♥←$y General Manager at Haibu Pharmaceut±↔↔≈ical)

　　"ADC Drug Small Molecule ↕σ®CMC R&D & Regulation"®®<>

　　As ADC becomes a ho‍★φλt topic in drug development i↕​↑σt increasingly attracts attention✘>• from pharmaceutical companieπβ∑s while small molecules serve asδ→↓¶ important intermediates within AD™>₹Cs also garnering significa↕>♣♦nt focus Design R&D surround♦πing small molecules primari↔♦  ly emphasizes suitable pharm↑→ €acokinetic properties control≥¶lable toxicity quality c€♣onsistency without signif∏±icantly impacting antibodi & es ensuring overall process c←βε ontrol quality stability post-introduct→₩ion small molecules Regulatory aspects←≠ focus mainly upon productio"×n process controllability sλε≈tability product quality consistency ∞​chiral structure verifi↕←cation comprehensive∏¶δness reasonableness limit settinα"∞g stability study thoγ₩↕roughness while also considering ¶‍ logical integrity withi≈±α£n studies Haibu possesses several  ♣σΩyears' experience developing linker pl✘σ<€atforms utilizing S2 series linke±γ€rs producing HB0321 series ADCs showing•ε÷¥ superior efficacy data both vitro mo&♠±use experiments indicating H♠¶B0321b c outperforming market✘☆≠ed ADC products antibo ↓♠≤dies Based upon our comprehensive exp$÷δeriences good linker design regulato÷≥↕ry considerations surrounding ​€¥small molecule R&D rep☆≈₹↓resent key influential factors toward✔$↓≈s successful ADC drug ou ≥tcomes.

Sharing Exchange

　　After thematic reports all attending  €∞guests freely shared di♠λ₽scussions concluding successfε→←§ully "Pharmaceutical Innovation For‍¶∞✔um ,2023 New Year Sharing Exchange Meet±¶®‌ing" amidst relaxed enjo‍¶yable exchanges.

　　With technological advancements iΩ©ncreased policy suppγ✔ort activity within capital ×₹♠≥markets domestic pha©×¥ rmaceutical innovation step©≠s into leap period transition₹'$γing from quantitative growth t‌♠owards qualitative enhancement some secγ"tors begin leading rather than mere∞‍®ly following or keep₩≈↑ing pace Winter's chi™λ☆ll experienced during twenty twenty-tw≠ £o gradually recedes behind us Sp✘↓ring's warmth extends forward b$$©♦eneath our feet Even amidst cu¶>↔βrrent winter we shall approach su•©nlight welcoming brighter days ahead.